These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 1950097)
1. The protective role of humoral neutralizing antibody in the NIH potency test for rabies vaccines. Wunderli PS; Shaddock JH; Schmid DS; Miller TJ; Baer GM Vaccine; 1991 Sep; 9(9):638-42. PubMed ID: 1950097 [TBL] [Abstract][Full Text] [Related]
2. Alum adjuvanted rabies DNA vaccine confers 80% protection against lethal 50 LD Garg R; Kaur M; Saxena A; Prasad R; Bhatnagar R Mol Immunol; 2017 May; 85():166-173. PubMed ID: 28267643 [TBL] [Abstract][Full Text] [Related]
3. Effects of vaccine route and dosage on protection from rabies after intracerebral challenge in mice. Wunderli PS; Dreesen DW; Miller TJ; Baer GM Am J Vet Res; 2003 Apr; 64(4):491-8. PubMed ID: 12693542 [TBL] [Abstract][Full Text] [Related]
4. Overexpression of Interleukin-7 Extends the Humoral Immune Response Induced by Rabies Vaccination. Li Y; Zhou M; Luo Z; Zhang Y; Cui M; Chen H; Fu ZF; Zhao L J Virol; 2017 Apr; 91(7):. PubMed ID: 28100620 [TBL] [Abstract][Full Text] [Related]
5. Rabies DNA vaccination by the intranasal route in dogs. Tesoro Cruz E; Hernández González R; Alonso Morales R; Aguilar-Setién A Dev Biol (Basel); 2006; 125():221-31. PubMed ID: 16878480 [TBL] [Abstract][Full Text] [Related]
6. Addition of C3d-P28 adjuvant to a rabies DNA vaccine encoding the G5 linear epitope enhances the humoral immune response and confers protection. Galvez-Romero G; Salas-Rojas M; Pompa-Mera EN; Chávez-Rueda K; Aguilar-Setién Á Vaccine; 2018 Jan; 36(2):292-298. PubMed ID: 29191739 [TBL] [Abstract][Full Text] [Related]
7. A model in mice for the study of the early death phenomenon after vaccination and challenge with rabies virus. Blancou J; Andral B; Andral L J Gen Virol; 1980 Oct; 50(2):433-5. PubMed ID: 7463005 [TBL] [Abstract][Full Text] [Related]
8. Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody. Dietzschold B; Tollis M; Rupprecht CE; Celis E; Koprowski H J Infect Dis; 1987 Nov; 156(5):815-22. PubMed ID: 3655404 [TBL] [Abstract][Full Text] [Related]
9. G-protein based ELISA as a potency test for rabies vaccines. Chabaud-Riou M; Moreno N; Guinchard F; Nicolai MC; Niogret-Siohan E; Sève N; Manin C; Guinet-Morlot F; Riou P Biologicals; 2017 Mar; 46():124-129. PubMed ID: 28214171 [TBL] [Abstract][Full Text] [Related]
10. Rabies DNA vaccine encoding lysosome-targeted glycoprotein supplemented with Emulsigen-D confers complete protection in preexposure and postexposure studies in BALB/c mice. Kaur M; Saxena A; Rai A; Bhatnagar R FASEB J; 2010 Jan; 24(1):173-83. PubMed ID: 19741168 [TBL] [Abstract][Full Text] [Related]
11. Development and evaluation of a competitive ELISA for estimation of rabies neutralizing antibodies after post-exposure rabies vaccination in humans. Muhamuda K; Madhusudana SN; Ravi V Int J Infect Dis; 2007 Sep; 11(5):441-5. PubMed ID: 17321182 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of immune responses against rabies virus by monoclonal antibodies directed against rabies virus antigens. Schumacher CL; Ertl HC; Koprowski H; Dietzschold B Vaccine; 1992; 10(11):754-60. PubMed ID: 1441731 [TBL] [Abstract][Full Text] [Related]
13. Immune responses of mice to inactivated rabies vaccine administered orally: potentiation by Quillaja saponin. Maharaj I; Froh KJ; Campbell JB Can J Microbiol; 1986 May; 32(5):414-20. PubMed ID: 3719460 [TBL] [Abstract][Full Text] [Related]
14. Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier. Xiang ZQ; Gao GP; Reyes-Sandoval A; Li Y; Wilson JM; Ertl HC J Virol; 2003 Oct; 77(20):10780-9. PubMed ID: 14512528 [TBL] [Abstract][Full Text] [Related]
15. Nanogram quantities of plasmid DNA encoding the rabies virus glycoprotein protect mice against lethal rabies virus infection. Ray NB; Ewalt LC; Lodmell DL Vaccine; 1997 Jun; 15(8):892-5. PubMed ID: 9234541 [TBL] [Abstract][Full Text] [Related]
16. Vaccination challenge studies with variants of street rabies virus isolated in Nigeria. Okoh AE; Umoh JU; Ezeokoli CD; Addo PB Vaccine; 1988 Feb; 6(1):19-24. PubMed ID: 3354253 [TBL] [Abstract][Full Text] [Related]
17. Protective antibody response of Balb/c mice to Bali rabies virus isolate propagated in BHK-21 cells. Astawa INM; Agustini NLP; Masa Tenaya IW; Aryawiguna IPGW J Vet Med Sci; 2018 Nov; 80(10):1596-1603. PubMed ID: 30210066 [TBL] [Abstract][Full Text] [Related]
18. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein. Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400 [TBL] [Abstract][Full Text] [Related]
19. The influence of homologous vs. heterologous challenge virus strains on the serological test results of rabies virus neutralizing assays. Moore SM; Ricke TA; Davis RD; Briggs DJ Biologicals; 2005 Dec; 33(4):269-76. PubMed ID: 16168666 [TBL] [Abstract][Full Text] [Related]
20. An immune stimulating complex (ISCOM) subunit rabies vaccine protects dogs and mice against street rabies challenge. Fekadu M; Shaddock JH; Ekström J; Osterhaus A; Sanderlin DW; Sundquist B; Morein B Vaccine; 1992; 10(3):192-7. PubMed ID: 1557935 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]